Contraception News and Research

Latest Contraception News and Research

Emory researchers present public health research findings at American Public Health Association meeting

Emory University Rollins School of Public Health researchers will present Nov. 11 on a range of topics at the American Public Health Association's annual meeting in Philadelphia, including a study that found reduced absenteeism among employees participating in a large-scale worksite wellness program.

11 Nov 2009

HIV/AIDS leading cause of death among women ages 15-44, WHO study shows

In follow-up coverage to the WHO's report on women's health, several news outlets examine the impact HIV/AIDS is having on women around the world. "In its first study of women's health, the World Health Organization said yesterday that the AIDS virus is the leading cause of death and disease among women between the ages of 15 and 44," the Associated Press/Boston Globe reports (11/10).

11 Nov 2009

Court denies preliminary injunction against Hologic, Conceptus to continue patent infringement suit

Conceptus, Inc., developer of the Essure® procedure, the first proven non-incisional permanent birth control method available, today announced that the United Stated District Court, Northern District of California has denied Conceptus’ motion for a preliminary injunction prohibiting Hologic, Inc. from importing, using, selling or offering to sell the Adiana system in the United States.

From Hologic, Inc. 10 Nov 2009

Affordable health care can save millions of women, newborns, and children in sub-Saharan Africa

The lives of almost 4 million women, newborns, and children in sub-Saharan Africa could be saved every year if well-established, affordable health care interventions reached 90 percent of families, according to a joint report by the national science academies of seven African countries.

10 Nov 2009

Warner Chilcott reports a net income of $424.2M for the quarter ended September 30, 2009

Warner Chilcott plc today announced its results for the quarter ended September 30, 2009. Revenue in the quarter ended September 30, 2009 increased 9.0% to $252.8 million over the prior year quarter. The primary drivers of the increase in revenue in the quarter were the net sales of LOESTRIN 24 FE and ESTRACE Cream which were partially offset by net sales declines of other products, primarily TACLONEX.

9 Nov 2009

Lubricants improve the comfort and pleasure of sexual intercourse, and reduce the risk of injury

An Indiana University study involving 2,453 women ages 18 to 68 found that lubricant use during sexual activity alone or with a partner contributed to higher ratings of pleasurable and satisfying sex.

9 Nov 2009

Educational video induces girls diagnosed with PID to ensure partner treatment

A study at Johns Hopkins Children's Center found that girls diagnosed with pelvic inflammatory disease (PID) who watched a short educational video were three times more likely to discuss their condition with their partners and to ensure partner treatment than girls diagnosed and treated without seeing the film.

5 Nov 2009

Interim data from Schering-Plough's narlaprevir Phase IIa study

Schering-Plough Corporation reported that interim results from an ongoing Phase IIa study of narlaprevir (SCH 900518), its investigational, once-daily protease inhibitor, demonstrated potent antiviral activity in treatment-naive patients with chronic hepatitis C virus (HCV) genotype 1.

3 Nov 2009

Study of combination therapy versus monotherapy for pulmonary arterial hypertension

Gilead Sciences, Inc., in collaboration with GlaxoSmithKline (GSK), today announced plans for an international, event-driven (morbidity and mortality) clinical trial to study combination therapy versus monotherapy in a first-line treatment setting for pulmonary arterial hypertension (PAH).

2 Nov 2009

Schering-Plough receives FDA complete response letter regarding PEGINTRON

Schering-Plough Corp. announced the U.S. Food and Drug Administration (FDA) has issued a complete response letter to the company's supplemental Biologics License Application regarding PEGINTRON® (pegylated interferon alfa-2b) for the adjuvant treatment of patients with stage III malignant melanoma after complete lymphadenectomy.

31 Oct 2009

Leading gynecologist recommends flu shots for pregnant women

Randy A. Fink, MD says pregnant women ought to be shot – with a flu vaccination needle. “A flu shot offers double protection to both mother and baby,” says Dr. Fink, a Miami board certified specialist who was recently named one of “America's Top Obstetrician/Gynecologists” by the Consumer Research Council.

30 Oct 2009

Girls' ethnicity and weight linked to participation in risky sexual behaviors

A University of Pittsburgh study sheds new light on the relationship between race, body weight and sexual behavior among adolescent girls. The results suggest that a girl's ethnicity and her actual weight or perception of her weight may play a role in her participation in risky sexual behaviors. The study results are published in the November issue of Pediatrics, now available online.

29 Oct 2009

Conceptus reports clinical success of its Essure non-incisional permanent birth control procedure

Conceptus, Inc., developer of the Essure® procedure, the first proven non-incisional permanent birth control method available, today announced that the clinical success of the Essure® procedure will be highlighted at the 18th Annual Congress of the European Society for Gynaecological Endoscopy (ESGE) in Florence, Italy from October 28-31, 2009.

29 Oct 2009

Intrauterine contraception is most popular amongst European women

A European study has defined the profile for the usage of long-acting contraceptive methods. The work, presented with the National Congress of Gynaecology award, shows, amongst other things, that 10% of women use these methods, the majority over 30 years old.

29 Oct 2009

New CCS guidelines and position papers for physicians and nurse practitioners

Several new guidelines and position papers offering the most up to date information to ensure that clinicians practice evidence-based medicine were released at the Canadian Cardiovascular Congress 2009 this week.

28 Oct 2009

Provisions in health care bill may transform nation's largest abortion chain into quasi-government status

The Senate version of America's Healthy Future Act of 2009 may transform the nation's largest abortion chain into a quasi-government entity for sex education.

28 Oct 2009

Oral contraceptives increase stroke risk but benefits still outweigh risks for most users

Nearly 100 million women worldwide use birth control pills. Pills now in use contain much lower concentrations of estrogens than older preparations. The relationship between oral contraceptives and stroke has been studied and debated for decades, and studies have yielded conflicting results.

27 Oct 2009

Theravance earns milestone payment for bactericidal, injectable lipoglycopeptide antibiotic

Theravance, Inc. announced today that it has earned a milestone payment of $20 million for the U.S. Food and Drug Administration (FDA) approval of VIBATIV (telavancin) and supplying its collaboration partner, Astellas Pharma US, Inc. (Astellas), with the launch inventory for the first commercial sale in the United States.

23 Oct 2009

IPS examines potential for future U.N. population meeting

Inter Press Service examines the possibility of another U.N. conference on development and population within the next five years. Despite progress made since the 1994 conference on population and development (ICPD), U.N. Secretary-General Ban Ki-Moon recently noted more than 200 million women cannot access safe and effective contraception, and "too many women resort to unsafe abortions because they lack access to family planning," according to the news service.

20 Oct 2009

Positive data from BioSante Pharmaceuticals' LibiGel Phase III clinical development program

BioSante Pharmaceuticals, Inc., today announced positive safety data in its ongoing LibiGel Phase III clinical development program. For the first time, unblinded data have been reviewed by the independent DMC of the LibiGel Cardiovascular and Breast Cancer Safety Study. Based on this review of unblinded data, the DMC unanimously recommended continuation of the study as described in the study protocol, with no modifications.

20 Oct 2009

Contraception News and Research

Latest Contraception News and Research

Emory researchers present public health research findings at American Public Health Association meeting

HIV/AIDS leading cause of death among women ages 15-44, WHO study shows

Court denies preliminary injunction against Hologic, Conceptus to continue patent infringement suit

Affordable health care can save millions of women, newborns, and children in sub-Saharan Africa

Warner Chilcott reports a net income of $424.2M for the quarter ended September 30, 2009

Lubricants improve the comfort and pleasure of sexual intercourse, and reduce the risk of injury

Educational video induces girls diagnosed with PID to ensure partner treatment

Interim data from Schering-Plough's narlaprevir Phase IIa study

Study of combination therapy versus monotherapy for pulmonary arterial hypertension

Schering-Plough receives FDA complete response letter regarding PEGINTRON

Leading gynecologist recommends flu shots for pregnant women

Girls' ethnicity and weight linked to participation in risky sexual behaviors

Conceptus reports clinical success of its Essure non-incisional permanent birth control procedure

Intrauterine contraception is most popular amongst European women

New CCS guidelines and position papers for physicians and nurse practitioners

Provisions in health care bill may transform nation's largest abortion chain into quasi-government status

Oral contraceptives increase stroke risk but benefits still outweigh risks for most users

Theravance earns milestone payment for bactericidal, injectable lipoglycopeptide antibiotic

IPS examines potential for future U.N. population meeting

Positive data from BioSante Pharmaceuticals' LibiGel Phase III clinical development program

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Contraception News and Research

Latest Contraception News and Research

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Newsletters you may be interested in